Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




GENpoll: Jan 11, 2012

Prometheus v. Mayo

What will the Supreme Court decide in this much-watched molecular diagnostic lawsuit?

In Favor of Prometheus
 
  20.0%
In Favor of Mayo
 
  70.0%
Split decision
 
  0.0%
Undecided
 
  10.0%

Suggest a Poll
« More Polls » « View Results »

During oral arguments before the U.S. Supreme Court in a case being watched closely by molecular diagnostics companies, justices repeatedly asked lawyers for Prometheus Laboratories and Mayo Collaborative Services for direction on the key question wrought by the patent litigation: When does a claim involving diagnostic and treatment-related chemical observations, among examples of natural phenomena, meet the threshold for patent eligibility?

The justices didn’t get the clear answer they sought. Now it will be up to the nine to answer the question as they decide Prometheus v. Mayo by looking to the law to determine what intellectual property molecular diagnostics companies can and cannot patent. What do you think?

Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll